Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Galactosemia

What is Galactosemia?

Galactosemia is a family of genetic disorders which affect how the body processes a simple sugar called galactose. Specifically, it affects the body’s ability to convert galactose (a sugar present in milk, including human breast milk) to glucose (a different kind of sugar that your body uses for energy). Individuals with galactosemia have disruptions or mutations in certain genes, which affect the different enzymes involved in breaking down galactose. Early diagnosis and treatment is critical, especially in newborns, to avoid life-threatening complications and health problems. Researchers have identified several types of galactosemia. Classic galactosemia (type I) is the most common and most severe type, which is caused by a deficiency in an enzyme called Galactose-1 phosphate uridyl transferase (GALT).

 

Galactosemia is a family of genetic disorders which affect how the body processes a simple sugar called galactose. Specifically, it affects the body’s ability to convert galactose (a sugar present in milk, including human breast milk) to glucose (a different kind of sugar that your body uses for energy). Individuals with galactosemia have disruptions or mutations in certain genes, which affect the different enzymes involved in breaking down galactose. Early diagnosis and treatment is critical, especially in newborns, to avoid life-threatening complications and health problems. Researchers have identified several types of galactosemia. Classic galactosemia (type I) is the most common and most severe type, which is caused by a deficiency in an enzyme called Galactose-1 phosphate uridyl transferase (GALT).

Acknowledgement of Galactosemia has not been added yet.

The most common type of galactosemia (classic or type I) is diagnosed in the range of 1 in 30,000 to 1 in 48,000 births through newborn screening programs around the world. The other types of galactosemia are less common with type II likely occurring in fewer than 1 in 100,000 newborns and type III being very rare. The disease has been reported in all ethnic groups, but clinical variant galactosemia occurs most often in individuals of African descent and native Africans in South Africa with the specific GALT gene mutation. There seems to be an increased frequency of galactosemia in individuals of Irish ancestry.

Synonyms for Galactosemia has not been added yet.

Galactosemia is an autosomal recessive genetic disorder, whereby a child must inherit one defective gene from each parent to develop the disease. It is a carbohydrate metabolic disorder caused by disruptions or mutations in the GALT, GALK1, and GALE genes. These genes provide instructions for making enzymes that are responsible for breaking down galactose into glucose, and other molecules the body can store for energy use. The following are types of Galactosemia and can cause different patterns of signs and symptoms:

  • Type I (Classic Galactosemia) - This is the most common and severe type caused by a deficiency in Galactose-1 phosphate uridyl transferase (GALT). 
  • Type II (Galactokinase deficiency) - This is due to a deficiency of galactose kinase (GALK/GALK1).
  • Type III (Galactose Epimerase deficiency) - This is due to a deficiency of galactose-6-phosphate epimerase (GALE).

 

Common symptoms and signs of classic galactosemia in infants can include feeding difficulties, lack of energy, failure to gain weight and grow, jaundice, liver damage, abnormal bleeding. abdominal pain, progressive sensorineural deafness, and amyloidosis (a rare disease in which abnormal proteins called amyloids build up and form deposits in organs, resulting in organ malfunction and eventually failure). In severe cases, bacterial infections (sepsis) and shock can occur.Type II Galactosemia causes fewer medical complications than classic galactosemia with affected infants developing cataracts but otherwise developing fewer long-term medical problems. Type III galactosemia can vary from mild to severe and can include cataracts, delayed growth and development, liver disease and kidney problems.

Classic galactosemia can be diagnosed when elevated levels of galactose-1-phosphate are found in red blood cells, and there is reduced GALT enzyme activity. In most infant cases, galactosemia can be diagnosed in newborn screening programs by using a small blood sample from the heel stick test (a test performed on newborns, in which a baby’s heel is pricked to collect a small sample of blood for testing).

Molecular genetic testing may be used to identify mutations in the GALT gene. 

A GALT isoelectric-focusing electrophoresis test for specific molecular diagnosis (this is a technique commonly used in laboratories to separate charged molecules, such as DNA according to size) and can be used to predict the GALT phenotype of an individual. The most common GALT mutation in white Europeans and North Americans replaces the amino acid glutamine with the amino acid arginine at position 188 in the enzyme (written as Gln188Arg or Q188R). Another mutation occurs almost exclusively in people of African descent, in which the amino acid leucine is replaced by the amino acid serine at position 135 (written as Ser135Leu or S135L).

 

There is no cure for galactosemia. Standard treatment for individuals with galactosemia involves following a lactose-restricted diet with lactose-free milk substitutes.

 

Children with galactosemia are at increased risk of delayed development, cataracts, speech difficulties, and intellectual disability. Depending on the severity of the condition, some children may require educational assistance, speech therapy, and hormone replacement therapy in cases of delayed puberty. Genetic counselling may be recommended in some families with children who have galactosemia.

Tips or Suggestions of Galactosemia has not been added yet.

National Organization for Rare Disorders. Galactosemia. 2019. Available from: https://rarediseases.org/rare-diseases/galactosemia/

Saleem, U., et al. Prevalence, Epidemiology and Clinical Study of Galactosemia. Journal of Applied Pharmacy. 2012. Available from: https://www.longdom.org/open-access/prevalence-epidemiology-and-clinical-study-of-galactosemia-.pdf

U.S. National Library of Medicine. Galactosemia. 2020. Available from: https://ghr.nlm.nih.gov/condition/galactosemia

U.S. National Library of Medicine. GALT Gene. 2020. Available from: https://ghr.nlm.nih.gov/gene/GALT#conditions

Community Details Update Created by RareshareTeam
Last updated 14 Sep 2020, 01:04 PM

Posted by RareshareTeam
14 Sep 2020, 01:04 PM

Hi everyone,

The Galactosemia community details have been updated. We added more information about the cause, prevalence, symptoms, diagnosis, treatment and prognosis. Hopefully, you find it helpful! 

Community Resources
Title Description Date Link

Clinical Trials


Cords registry

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.

Enrolling is easy.

  1. Complete the screening form.
  2. Review the informed consent.
  3. Answer the permission and data sharing questions.

After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.

Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.

Visit sanfordresearch.org/CoRDS to enroll.

Community Leaders

 

Expert Questions

Ask a question

Community User List

Mother of CG Baby

 

I am a mother of 5, Grandmother to 4. I am raising my grandson Donavon who has Galactosemia. I am one of the biggest advocates in raising awareness for Rare diseases and Galactosemia

Start a Community


Don't See Your Condition On Rareshare?

Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.

FAQ


Have questions about rareshare?

Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.

Discussion Forum

Community Details Update

Created by RareshareTeam | Last updated 14 Sep 2020, 01:04 PM


Communities

Our Communities

Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.

FIND YOUR COMMUNITY
Physicians

Our Resources

Our rare disease resources include e-books and podcasts

VIEW OUR EBOOKS

LISTEN TO OUR PODCASTS

VIEW OUR GUIDES

Leaders

Our Community Leaders

Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.